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likely to start with combination pharmacotherapy. Patients who are older than 65, 
and those who have hypertension were less likely to start with combination pharma-
cotherapy. CONCLUSIONS: Patients on combination were more likely to switch, less 
likely to discontinue than mono-pharmacotherapy. Age, gender, and co-morbidities 
were predictors of receiving combination pharmacotherapy in DPN patients.
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OBJECTIVES: Patients with specialty conditions are faced with a unique set of chal-
lenges in regard to being adherent to their medications. One-on-one pharmacist 
counseling from the comfort of the patient’s home can be an innovative and impact-
ful intervention that can lead to improved adherence for specialty patients. This 
study analyzes the impact on adherence after an initial video conferencing session 
between pharmacist and patient at the start of treatment. METHODS: Patients new 
to therapy receiving a video conferencing session from the BriovaRx® specialty 
pharmacy from April 1, 2013 – May 31, 2014 were included in the analysis. The com-
parison group consisted of non-BriovaRx® patients that were also new to therapy 
during this timeframe and continuously eligible from October 1, 2012 – November 
30, 2014. The two groups of patients were matched on age, gender, and therapy. 
Adherence as measured by cumulative medication gap (CMG) was measured for 
both groups for 180 days after the start of treatment. The odds ratio was computed to 
assess the likelihood of a patient having an adherence greater than or equal to 80% 
with and without the video consultation. RESULTS: There were a total of 77 patients 
who received a video consultation and 117 total drug regimens. The distribution 
of disease states included: 25% hepatitis C, 22% rheumatoid arthritis, 18% multiple 
sclerosis and 35% other specialty conditions. The average age of patients receiving 
a consult was 46 with 56% female. The control group consisted of 1,465 patients and 
1,736 total drug regimens. Patients had significantly higher odds of being adherent 
if they received a video consult (OR= 2.04; 95% CI, 1.02-4.07). CONCLUSIONS: This 
study highlights the benefit that video consultations can have on the adherence of 
specialty pharmacy patients. This is especially important given the high cost and 
complex management of specialty medications.
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Wang V, Hanger M, Woyczynski M, Vaughan T, Wicks P PatientsLikeMe, Cambridge 
MA, USA. OBJECTIVES: (1) To understand the utility of using patient-reported data 
from an online Systemic Lupus Erythematosus (SLE) community for research, 
and (2) to understand the experience of living with SLE, including symptoms and 
treatments in a real-world environment. METHODS: Drawing on data captured by 
PatientsLikeMe, we explored reported patient symptoms, side-effects, treatments, 
and reasons for stopping treatment. We generated Kaplan-Meier curves of treatment 
duration for patients reporting particular side effects. Finally, to infer additional 
symptom and treatment factors that were important to SLE patients, we analyzed 
free text in patient forums and profiles. RESULTS: At the time of the research, 
PatientsLikeMe was being used by 5,714 SLE patients. With 2,570 PLM members with 
SLE (45%) reporting symptoms, lower back pain (53%), fatigue (52%), and joint pain 
(45%) were most likely to be rated as severe. In Forums, patients discuss pain, both 
general and localized, more than other frequently-measured symptoms, such as 
malar rashes. Of 5,026 members (88%) reporting treatments, hydroxychloroquine 
(73%), prednisone (63%), and OTC Naproxen (41%) were the most commonly used. 
Azathioprine, naproxen, and belimumab treatments were most often abandoned 
due to lack of efficacy, whereas hydroxychloroquine and methotrexate were more 
often abandoned due to side-effects. CONCLUSIONS: This study supports the ability 
of an online platform to capture important information on patient experience of 
disease and treatment, particularly in a poorly understood area such as lupus. Given 
the severity of side effects and abandonment of treatments, there is unmet need in 
SLE treatment. Clinical trials have often focused on easily measurable endpoints 
(e.g., rashes), but symptoms such as pain and fatigue are worthy of deeper study. 
Research that reflects the the most common and severe symptoms will encourage 
development of higher-value lupus treatments.
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OBJECTIVES: Utility values are required to conduct cost-utility analyses for the eco-
nomic evaluation of novel therapies. While preference-based utility measures, such 
as the EQ-5D, are preferred by healthcare payers, they may inadequately capture 
condition-specific differences in health-related quality of life (HRQoL) or may not be 
available from clinical trials. Utility values for patients with polycythemia vera (PV), 
a myeloproliferative neoplasm (MPN), are not available in the literature; however, the 
PV RESPONSE trial collected EORTC QLQ-C30 and MPN-SAF data. The objective of the 
current study was to estimate utility values for PV patients using existing mapping 
algorithms. METHODS: EORTC QLQ-C30 data from the RESPONSE trial were mapped 
onto the EQ-5D using published mapping algorithms for various cancers (e.g., mul-
tiple myeloma, breast, gastric, esophageal). Utility values were also estimated using 
the MF-8D, a condition-specific preference-based measure that was developed for 
myelofibrosis, another MPN, using both the EORTC QLQ-C30 and MF-SAF. Utility 
values obtained from the various mapping algorithms were compared. RESULTS: 
At baseline in the RESPONSE trial, utility values calculated for PV patients using 
OBJECTIVES: Chronic back pain is a common health problem which is associated 
with considerable costs in United States. The largest categories for pain therapy 
costs include NSAID analgesics and opioids. However there has been limited 
evidence outlining the effectiveness in terms of quality of life of patients taking 
these pain medications for treating chronic back pain.Objective of this study is to 
perform a cost-utility analysis of chronic back pain patients using NSAIDS versus 
those using opioids alone and/ or combination opioid analgesics. METHODS: This 
cross sectional, observational, cost utility study was conducted using the Medical 
Expenditure Panel Survey database. Adult’s ≥ 18 years with chronic back pain diag-
nosis (identified by ICD-9 –CM codes) for atleast 3 consecutive rounds were included 
in the study. The study was conducted from a payer’s perspective and only the 
direct costs were included . Utility was measured using SF-6D scores from the SF-12 
questionnaire. RESULTS: 1340 chronic back pain patients were identified from 2012 
MEPS database, of which 53% (n= 704) were in NSAIDS group and 47% (n= 636) were 
in opioids group. The total mean cost of NSAIDs group was found to be $ 8005.3 
while the total mean cost of opioids group was found to be $12475, 99. The QALYs 
of both the groups was almost the same with the mean QALY score of NSAIDs group 
being 0.645 and the opioids group being 0.615. CONCLUSIONS: Preliminary analysis 
showed that for the extra cost spent on Opioids, the effectiveness was seen to be 
almost the same as those taking NSAIDS. This may be because of the severe adverse 
events associated with the use of opioids which may reduce the quality of life of 
patients. Further research needs to be conducted by considering other pharmaco-
logical agents used to treat back pain and finding the most cost effective treatment.
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OBJECTIVES: Tuberous sclerosis complex (TSC) is a rare genetic disorder associated 
with angiomyolipomata (non-malignant kidney lesions) in the majority of patients. 
Angiomyolipomata increase in size over time, present risk of acute hemorrhage, and 
can lead to progressive chronic kidney disease (CKD). Our objective was to document 
the association between angiomyolipomata and CKD, including the impact on health 
care resource utilization (HCRU) and health care costs. METHODS: This retrospective, 
longitudinal cohort study used medical chart data from patients with TSC treated at 
a specialty center in the Netherlands from January 1990 to April 2012. Patients were 
followed longitudinally and classified into open cohorts based on their CKD stage 
(estimated from serum creatinine levels) and size and number of angiomyolipomata. 
Average glomerular filtration rates (GFR) and the proportions of patients reaching 
advanced CKD stages were compared with a non-TSC reference population. HCRU 
rates and health care costs (2012€ ) per patient per year (PPPY) were compared across 
cohorts. RESULTS: 369 patients were included (median [mean] follow-up time 15.4 
[14.3] years). Compared with the non-TSC reference population, the decline in kidney 
function with age was steeper for patients with TSC (mean change in GFR/year= -1.53 
vs. -0.94 mL/min/1.73 m2), and more patients with TSC reached CKD stage 3 or higher 
(16% vs. 3% of patients < 70 years old). Compared with CKD stage 1, CKD stages 2 to 5 
were associated with larger and more numerous angiomyolipomata, higher overall 
HCRU rates (rate ratios= 1.5 to 2.3, P≤ 0.01), and higher health care costs (incremen-
tal costs= € 737 to € 30,641 PPPY, P≤ 0.004). CONCLUSIONS: Our results suggest that 
impaired kidney function associated with angiomyolipomata imposes a significant 
burden and remains a key concern in patients with TSC. Treatments that slow the rate 
of kidney function decline in patients with TSC may substantially reduce the HCRU 
and costs associated with CKD and angiomyolipomata.
SYStemIc dISorderS/condItIonS – Patient-reported outcomes & Patient 
Preference Studies
PSY44
characterIStIcS of combInatIon PharmacotheraPY In PatIentS wIth 
dIabetIc PaInfUl neUroPathY (dPn)
Kuo K., Brixner D., Lipman A., Hung M., Oderda G.
University of Utah, Salt Lake City, UT, USA
OBJECTIVES: To compare patient characteristics between DPN patients receiv-
ing mono-pharmacotherapy and those receiving combination pharmacother-
apy. METHODS: A patient cohort was identified diagnosed with DPN during 2006-2013 
in Inovalon’s MORE2® registry, a healthcare data warehouse with national medi-
cal/pharmacy claims, continuously enrolled for at least 18 months. Patients were 
included if they were ≥ 18 years at the time of their first DPN prescription for tricyclic 
antidepressant (TCAs), opioids, duloxetine, gabapentin, pregabalin, or lidocaine. They 
were classified as having mono- or combination pharmacotherapy (time between 
the first and second medicine was within 30 days). If there was 60-day prescription-
filled gap, the prescription was classified as discontinued. Switch or add-on groups 
were categorized based on continuation of the index medicine. A simple proportional 
hazards model was conducted for comparing time to discontinuation, switch, or 
add-on. Multiple logistic regression was used for identifying predictors of combi-
nation pharmacotherapy. RESULTS: There were 7,145 patients on mono-pharma-
cotherapy, and 421 patients on combination pharmacotherapy. The top three index 
medicines were gabapentin (55.7%), opioids (13.1%), and pregabalin (12.9%) in the 
mono-pharmacotherapy group, and opioids+ gabapentin (27.1%), TCAs+ gabapen-
tin (17.6%), and duloxetine+ gabapentin (8.6%) in combination group. Patients on 
combination pharmacotherapy were 57% less likely to discontinue than patients 
on mono-pharmacotherapy (95%CI = 0.34-0.54, p< 0.001), and 916% more likely to 
switch than patients on mono-pharmacotherapy (95%CI = 8.30-12.43, p< 0.001).There 
was no statistically significant difference in time to add-on (p= 0.069). Patients who 
are female, with > 7 co-morbidities, and who had depression, or arthritis were more 
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brochures to access a web-based survey (May 5-July 18, 2014) of demographic & 
disease characteristics, respondents’ lifestyle & health ratings, and their percep-
tion of IV infusions before and after initiating therapy. The analysis was exploratory 
and descriptive; data collected was a self-reported ordinal (scale, low-high, 1-10) 
with medians (IQR) reported. A stepwise (backward) multinomial logistic regres-
sion was conducted to determine predictors of a positive perception of IV infu-
sions. RESULTS: There were 1,762 respondents from 10,000 distributed brochures 
(18%). The majority of patients were: bio-naïve, employed, busy/active, and treated 
for inflammatory bowel disease. Median current health rating was high 8(6-9). The 
perception of IV infusions improved from initial treatment; majority of patients 
rated it as 5/10 prior to starting therapy vs. 8/10 after multiple infusions (p< 0.0001). 
Predictors of a positive IV experience were ‘satisfaction with the PSP coordina-
tor’ (OR= 3.0, 95% CI= 1.5-5.7) and ‘receiving an accurate description of treatment 
through the PSP from a physician’ (OR= 3.6, 95%CI= 2.2-5.9). CONCLUSIONS: 
Although there is selection bias, we found that patients have a positive experience 
with the PSP and report significant improvements in their perception of IV infusion. 
Regression analysis suggests that providing patients with an accurate description of 
the treatment at the PSP can improve the perception of the IV experience.
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OBJECTIVES: Intravenous infusions (IV) vs. subcutaneous injection (SQ) biologic 
products offer advantages and disadvantages to patients with inflammatory bowel 
disease (IBD). This study examines potential predictors of IV vs. SQ openness/pref-
erence among patients with IBD. METHODS: Patients (n= 263) completed a self-
administered, web-based questionnaire assessing demographics, health, disease, 
treatment characteristics, behaviors, and attitudes. Patients included: U.S. adults 
(aged ≥ 18) diagnosed with ulcerative colitis (UC; n= 140), Crohn’s disease (CD; n= 123), 
receiving immunomodulator treatment, but biologics-naïve. Chi square and t tests 
compared patients open vs. not open or preferring vs. not preferring IV. Logistic 
regression models predicted openness and preference as a function of potential pre-
dictors. RESULTS: Among all patients (mean age= 45.8, 57.1% female, 23.5% minority, 
and mean years since diagnosis= 10.7), 74.2% were open to starting biologics after 
discussion with their physicians, 64.6% (n= 170) were open to IV, and among those, 
34.7% (n= 59) preferred IV vs. SQ. Potential predictors of openness to IV included: 
considering one’s physician’s advice to be very-to-extremely influential for treat-
ment decisions (OR= 4.67; 1.87-11.64), male vs. female (OR= 2.94; 1.41-6.10), number 
of emergency room, hospital, and/or physician visits for UC/CD in the past 6 months 
(OR= 1.24; 1.07-1.43), ever experiencing fever as UC/CD sign/symptom (OR= 2.81; 1.21-
6.52), and awareness of infusion for UC/CD (OR= 2.38; 1.10-5.16); intention to delay 
biologics treatment due to safety perceptions inhibited openness to IV (odds ratio 
[OR]= 0.48; 95% confidence interval [CI]: 0.35-0.66); all p< .03. Potential predictors 
of preference for IV over SQ included: higher relative openness to office/hospital/
medical facility vs. home site of care (OR= 5.72: 3.51-9.31), receiving/ever having 
received infusion (OR= 4.11; 1.31-12.95), and detailed discussion of redness/swelling 
after injection (OR= 4.15; 1.29-13.39), all p< .02. CONCLUSIONS: The current study 
helps inform patient characteristics, attitudes, and disease and treatment history 
indicating interest in IV biologics treatment, which can help enable shared decisions 
to best benefit patients with IBD.
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OBJECTIVES: To investigate the relationship between patient-reported outcomes 
and durability of response using data from a phase 2 study of single-agent ibrutinib 
for patients with previously-treated MCL. METHODS: The phase 2 SPARK study 
evaluated the efficacy and safety of single-agent ibrutinib in patients with MCL who 
had received a rituximab-containing regimen and had progressed after ≥ 2 cycles of 
bortezomib therapy. In this multicenter, single-arm study, patients were enrolled to 
receive 560 mg/day ibrutinib continuously until progressive disease (PD) or unac-
ceptable toxicity. The primary end point was the overall response rate in response-
evaluable patients, as assessed by an Independent Review Committee. Secondary 
end points included patient-reported outcomes (FACT-Lym). RESULTS: Overall, 25 
of 110 evaluable patients (22.7%) were considered to have primary resistant disease 
(PD at first disease evaluation), with 85 of 110 (77.3%) considered as “responders”: 
22 patients (20%) were considered to have moderate response (stable disease [SD] 
or better, but with PD within 12 months; MR group), and 63 patients (57.3%) were 
considered to have durable response (SD or better, maintained for > 12 months; 
DR group). Median progression-free survival for the total evaluable population 
was 10.5 months; 4.1 months for the MR group and 16.8 months for the DR group. 
Additionally, 67 of 109 response-evaluable patients who had PRO results (61.5%) 
achieved a clinically-meaningful improvement in lymphoma symptoms based on 
EORTC QLQ-C30 cancer mapping algorithms ranged from 0.70 to 0.92. Utility values 
derived from the two versions of the MF-8D were also within this range, at 0.79 
(equal weighting) and 0.73 (Rasch weighting). Clinical opinion indicated that the 
MF-8D captures the key symptoms of PV (e.g., pruritus, abdominal pain/discomfort, 
bone pain, night sweats) better than the other cancer algorithms. CONCLUSIONS: 
The MF-8D may be more appropriate than other cancer algorithms for estimating 
utility values for PV patients, as it includes the most important symptoms of PV. 
This measure is expected to better capture treatment-specific differences affect-
ing HRQoL that are important for the economic evaluation of emerging therapies.
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OBJECTIVES: Hereditary haemochromatosis (HH) is a common autosomal reces-
sive disorder amongst persons of European heritage. Elevated hepcidin production 
increases the absorption of dietary iron, which is stored in the parenchymal tissues 
of the heart, liver and pancreas. Treatment consists of regular venepuncture, and if 
implemented early, prevents organ damage. If untreated, iron overload can be a cause 
of morbidity and mortality. To date, a lack of robust health economic evidence has 
been cited as one of the barriers to establishing screening programs for HH. Previous 
analyses have used unvalidated estimates of health state utility values (HSUV). This 
is in part due to no published estimates of HSUV. This study sought to estimate HSUV 
directly from people with different levels of severity of HH of in Australia. METHODS: 
Volunteers with HH were recruited to complete a web-based survey as part of a 
national cost of illness study for HH. HSUV was estimated using the Assessment of 
Quality of Life 4D (AQOL-4D) instrument. Severity of HH was categorised according 
to the method recommended by the European Association of the Study of the Liver. 
Multivariate regression analysis was performed to identify parameters associated 
with HSUV. RESULTS: Between November 2013 and November 2014, 221 people com-
pleted the survey. Increasing severity of HH was negatively associated with HSUV. 
Mean (standard deviation) HSUV were 0.76 (0.21), 0.81 (0.18), 0.60 (0.27), and 0.50 (0.27) 
for grades 1-4 HH respectively. CONCLUSIONS: Increasing severity of HH is associated 
with decreasing HSUV. Previous cost utility analyses have used higher HSUV which 
likely resulted in underestimates of the cost effectiveness of screening programs 
for HH. The HSUV reported in this paper are the most robust available and their use 
would improve the validity of future economic models for HH.
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OBJECTIVES: To assess the health status of haemophilia B patients treated with 
nonacog beta pegol, a novel recombinant Factor IX (FIX) product with prolonged 
half-life and less frequent dosing requirements. METHODS: Severe/moderate hae-
mophilia B (FIX activity level ≤ 2%) is an inherited bleeding disorder characterised 
by recurrent, often spontaneous bleeding episodes, in particular musculoskeletal 
bleeds. Modern management includes self-infusion of FIX 2-3 times/week to prevent 
bleeds (prophylaxis) or on-demand treatment (OnD). Haemophilia B patients aged 
13-70 years were included in a single-blind phase 3 trial evaluating safety and effi-
cacy of nonacog beta pegol. Patients were treated OnD for 28 weeks, or randomised 
to once weekly prophylaxis with 10 or 40 IU/kg for 52 weeks. All patients completed 
the 3 level EuroQol-5 dimensions (EQ-5D-3L) at baseline and end-of-trial. EQ-5D VAS 
ranges from 0-100. Higher score represents better health status. Changes in scores 
were compared to no change using the Wilcoxon signed rank test. RESULTS: 74 
patients were included in the Full Analysis Set (15 OnD; 30 on prophylaxis with 10 
IU/kg dose and 29 on prophylaxis with 40 IU/kg). 56 patients were 18-70 years and 18 
were 13-17 years. A significant improvement in EQ-5D index score was observed in 
the overall set (mean change = 0.04, p= 0.016), but no significant change was observed 
for the different dose groups. In subset analysis of the high dose prophylaxis arm, 
mean EQ-5D VAS was 74.3±18.0 at baseline and 83.9±14.5 at end-of-trial, leading to 
a statistically significant improved mean change in score (p= 0.030). The change was 
non-significant in the OnD and low dose prophylaxis arms. CONCLUSIONS: In a 
phase 3 clinical trial, haemophilia B patients treated with the long-acting FIX nona-
cog beta pegol showed a significant improvement in their health status. Patients 
treated with the prophylaxis dose of 40 IU/kg/weekly demonstrated significant 
improvement in health status according to the EQ-5D VAS.
PSY50
USe of InflIxImab wIthIn a PatIent SUPPort Program: PoSItIve 
PercePtIon of Iv InfUSIonS from PatIentS’ PerSPectIve
Dyrda P.1, O’Reilly R.2, Williamson M.1, Dajnowiec D.1, Jones J.3, Borgaonkar M.4, Siffledeen J.5, 
Anger D.6, Thompson M.6
1Janssen Inc., Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Dalhousie 
University, Halifax, NS, Canada, 4Memorial University, St. John’s, NF, Canada, 5University of 
Alberta, Edmonton, AB, Canada, 6Cornerstone Research Group, Burlington, ON, Canada
OBJECTIVES: Patients with auto-immune diseases who are treated with infliximab 
(IFX) intravenous (IV) infusions are managed through a manufacturer-sponsored 
patient support program (PSP). Previous studies have had conflicting conclusions 
regarding patient preferences of modes of administration of biologics, with impli-
cations of negative perceptions of IV infusions. The aim of this study was to assess 
patients’ experience of IFX IV therapy administered in the PSP and to determine 
predictors of a positive perception of IV infusions. METHODS: In this nationwide, 
cross-sectional survey, patients currently receiving IFX within the PSP were given 
